Advisory: Alerts on positive data in Spago's phase IIa endometriosis trial repeat earlier story
Dec 20 (Reuters) - Please ignore alerts on positive data in Spago's SPAGO.ST phase IIa
endometriosis trial. The alerts repeat earlier story from Dec. 15, 2023 and will be withdrawn.
To see Reuters coverage of the news please follow the link urn:newsml:reuters.com:*:nFWN3D94J4
STORY_NUMBER: FWN3DE1F8
STORY_DATE: 20/12/2023
STORY_TIME: 07:46:24
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Spago Nanomedical AB (publ)
See all newsBrief: Spago Nanomedical Announces Outcome Of Rights Issue
Brief: Spago Nanomedical Resolves On Rights Issue Of About SEK 16 Million
Sweden's Spago Nanomedical Q1 loss narrows
Brief: Spago Nanomedical Q1 Sales SEK 22 Thousand
Brief: Spago Nanomedical Says Tumorad-01 Study Meets Primary Endpoint Of Maximum Tolerated Dose